AI 본문요약

엑셀 다운로드 AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

참고문헌 (21)

1. S. Gupta and L.-J. Crofford, An Update on specific COX-2 inhibitors: The COXIBs, Bulletin on the Rheumatic Disease., 50(1), 5245-5248 (2001) 

2. Rxlist, Mobic, Meloxicam, Pharmacology & Clinical review, US medicinal information 

3. M. Pairet, J. van Ryn, H. Schierok, A Mauz, G. Trummlitz and G. Engelhardt, Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomer. lnflamm Res., 47(6), 270-276 (1998) 

   상세보기

4. E-M. Andreas, K.-D. Christine, H. Nina, H. Stefan, S. Jens and K.-H. Juergen, Water-so;uble meloxicam granulates, PCT W02004037264 

5. K. Laura, P. John, C.-R. Eugene and R. Tuula, Nanoparticulate meloxicam formulations, US patent US2004229038 

6. S. Baroota, S.-P. Agarwal, Meloxicam complexation with ${\beta}$ -cyclodextrin: influence on the anti-inflammatory and ulcerogenic activity, 58, 73-74 (2003) 

   상세보기

7. N.-B. Naidu, K.P.R. Chowdary, K.Y.R. Murthy, Y. Satyanarayana, A.-R. Hayman and G. Heeket, Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems, Journal of Pharmaceutical and Biomedical Analysis, 35, 75-86 (2004) 

   상세보기

8. R. Banerjee, H. Chakraborty and M. Sarkar, Host-Guest complexation of oxicam NSAIDs with ${\beta}$ -cyclodextrin, Biopolymers, 75(4), 355-365 (2004) 

   상세보기

9. M.-M. Ghorab, H.-M. Abdel-Salam, M.-A EI-Sayad and M.-M. Mekhel, Tablet formulation containing meloxicam and beta-cyclodextrin: Mechanical characterization and bioavailability evaluation, AAPS Pharm. Sci. Tech., 27(5) , e59 (2004) 

10. J. Dequeker, and F. degner, Inflammation Research Editorial, lnflamm. Res., 50, Supplement 1 S3-S4 (2001) 

11. E.-M. Lemmel, W. Bolten, R. Burgos-Vargns, P. Platt, M. Nissila, D. Sahlberg, et al., Efficacy and safety of meloxicam in patients with rheumatoid arthritis, J. Rheumatopl., 24, 282-290 (1997) 

12. B. Lund, M. Dialel, R. Bluhmki and A double-blind, randomized placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. Scand J. Rheumatol, 27, 32-37 (1998) 

    상세보기

13. D. Vocum, D. Hall, and P. Ruszko, Meloxicam osteoarthritis team. Efficacy and safety of meloxicam in the treatment of osteoarthritis. Arthr Rheum., 42(Suppl), S147 (1999) 

14. M. Dougados, A. Gueguen, J.-P. Nakache, I. Veys, E.-M. Zeildler, et a!., Ankylosing spondylitis: What is the optimum duration of a clinical study? A one year versus a 6 weeks nonsteroidal anti-inflammatory drug trial. Rheumatology, 38, 235-244 (1999) 

    상세보기

15. D. Duchene, D. Wouessidiewe, Pharmaceutical uses of cyclodextrins and derivatives, Drug Dev. lnd. Pharm., 16, 2487-2499 (1990) 

    상세보기

16. O. Berkers, E.Y. Uijioridal, J.-H. Haijnen, A. Bult and W.-J. Underberg, Cyclodextrins in the pharmaceutical field. Drug Dev. lnd. Pharm. 17, 1503-1549 (1991) 

    상세보기

17. Ludipress, Technical information, BASF Chem. Co., Supersedes issue of October 2001, September, 2003 

18. Metolose SR (Hypromellose), Technical note, ShinEtsu Chem. Co., issued on October, 2002 

19. D.-X. Zhejiang, B. Xue and Y.-X. Ban. Investigation on release model of insoluble drug in hydroxypropyl methycellulose matrix tablets, 33(3), 225-228 (2004) 

20. B. Pose-Vilamovo, C. Rodriguez-Tenreiro, J.-F. Rosa dos Santos, J. Vazquez-Doval, A. Concheiro, C. Alvarez-Lorenzo and J.-J. Torres-Labandeira, Modulating drug release with cyclodextrins in hydroxypropyl methylcellulose gels and tablets. J. Control Release. 10;94(2-3), 351-363 (2004) 

21. R.-O. Williams 3rd, M.-A .Sykora and V. Mahaguna, Method to recover a lipophilic drug from hydroxypropyl methylcellulose matrix tablets. AAPS Pharm. Sci. Tech. Jun, 9;2(2):E8 (2001)